Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.

Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, Sancho JM, Ramírez MJ, Terol MJ, Capote FJ, Gutiérrez A, Sánchez B, López A, Salar A, Rodríguez-Caravaca G, Canales M, Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group).

Cancer Med. 2019 Oct 1. doi: 10.1002/cam4.2555. [Epub ahead of print]

2.

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Rodriguez A, Lorza L, Martín A, Coria E, López-Guillermo A, Salar A, José Lahuerta J; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Hematol Oncol Stem Cell Ther. 2019 Jul 9. pii: S1658-3876(19)30052-4. doi: 10.1016/j.hemonc.2019.06.001. [Epub ahead of print]

3.

Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.

Ferraro MP, Gimeno-Vazquez E, Subirana I, Gómez M, Díaz J, Sánchez-González B, García-Pallarols F, Martínez L, Ble M, Molina L, Belarte LC, Abella E, Elosua R, Comín-Colet J, Salar A.

Eur J Haematol. 2019 Jun;102(6):509-515. doi: 10.1111/ejh.13234. Epub 2019 Apr 23.

PMID:
30972815
4.

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, Setoain X, Rodríguez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jiménez-Ubieto A, Rodriguez A, González de Villambrosía S, Bello JL, López L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, González M, Martín A, Caballero MD, López-Guillermo A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO).

Br J Haematol. 2019 May;185(3):480-491. doi: 10.1111/bjh.15805. Epub 2019 Feb 22.

PMID:
30793290
5.

Gastric MALT lymphoma and Helicobacter pylori.

Salar A.

Med Clin (Barc). 2019 Jan 18;152(2):65-71. doi: 10.1016/j.medcli.2018.09.006. Epub 2018 Nov 10. Review. English, Spanish.

PMID:
30424932
6.

Expectant Mothers' Experiences with Lay Doulas in Maternity Units of Hospitals in Impoverished Areas of Iran: A Qualitative Study.

Safarzadeh A, Shafipour V, Salar A.

Iran J Nurs Midwifery Res. 2018 Nov-Dec;23(6):437-443. doi: 10.4103/ijnmr.IJNMR_109_17.

7.

Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Hematol Oncol. 2018 Dec;36(5):765-772. doi: 10.1002/hon.2553. Epub 2018 Sep 12. No abstract available.

PMID:
30129233
8.

Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.

Montalbán C, Díaz-López A, Martín A, Baile M, Sanchez JM, Sancho JM, García O, Novelli S, Monter-Rovira A, Salar A, Bastos M, Gutiérrez A, Bento L, Córdoba R, Arquero T, González de Villambrosia S, Barranco G, De Oña R, López Guillermo A, Rodriguez Salazar MJ, Domínguez JF, Fernández R, Queizan JA, Rodríguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators.

Br J Haematol. 2018 Aug;182(4):534-541. doi: 10.1111/bjh.15446. Epub 2018 Jul 5.

PMID:
29978453
9.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.

10.

Identifying self-care behaviors in middle-aged women: A qualitative study.

Ghaljaei F, Rezaee N, Salar A.

Electron Physician. 2017 Nov 25;9(11):5800-5805. doi: 10.19082/5800. eCollection 2017 Nov.

11.

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Hernández-Garcia MT, Novelli S, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.

Bone Marrow Transplant. 2018 Jun;53(6):780-783. doi: 10.1038/s41409-018-0096-6. Epub 2018 Jan 23. No abstract available.

PMID:
29362504
12.

Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galego A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Coria E, Rodriguez A, Martín A, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group.

Cancer Med. 2017 Dec;6(12):2766-2774. doi: 10.1002/cam4.1217. Epub 2017 Oct 26.

13.

Understanding the Contextual Factors Affecting Women's Health in Sistan and Baluchestan Province in Iran: A Qualitative Study.

Rezaee N PhD, Salar A PhD, Ghaljaei F PhD, Seyedfatem N PhD, Rezaei N Ma.

Int J Community Based Nurs Midwifery. 2017 Oct;5(4):317-328.

14.

Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, Ordóñez GR, Rovira J, Clot G, Royo C, Navarro A, Gonzalez-Farre B, Vaghefi A, Castellano G, Rubio-Perez C, Tamborero D, Briones J, Salar A, Sancho JM, Mercadal S, Gonzalez-Barca E, Escoda L, Miyoshi H, Ohshima K, Miyawaki K, Kato K, Akashi K, Mozos A, Colomo L, Alcoceba M, Valera A, Carrió A, Costa D, Lopez-Bigas N, Schmitz R, Staudt LM, Salaverria I, López-Guillermo A, Campo E.

Leukemia. 2018 Mar;32(3):675-684. doi: 10.1038/leu.2017.251. Epub 2017 Aug 14.

15.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C.

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. No abstract available.

PMID:
28801448
16.

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, Moreno M, Salar A, García-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Rodríguez A, Jiménez-Ubieto A, González de Villambrosia S, Bello JL, López L, Monsalvo S, Novelli S, de Cabo E, Infante MS, Pardal E, García-Álvarez M, Delgado J, González M, Martín A, López-Guillermo A, Caballero MD.

Br J Haematol. 2017 Sep;178(5):699-708. doi: 10.1111/bjh.14831. Epub 2017 Aug 7.

PMID:
28782811
17.

Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.

Sanchez-Gonzalez B, Torres E, Ferraro Rosset MP, Calafell M, Gale C, Martinez L, Sancho E, Garcia P, Gimeno E, Garcia-Pallarols F, Salar A.

Leuk Lymphoma. 2018 Apr;59(4):1019-1021. doi: 10.1080/10428194.2017.1349906. Epub 2017 Jul 21. No abstract available.

PMID:
28728440
18.

Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández-Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, López Jiménez J, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1631-1640. doi: 10.1016/j.bbmt.2017.05.021. Epub 2017 May 19.

19.

LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.

Colomo L, Vazquez I, Papaleo N, Espinet B, Ferrer A, Franco C, Comerma L, Hernandez S, Calvo X, Salar A, Climent F, Mate JL, Forcada P, Mozos A, Nonell L, Martinez A, Carrio A, Costa D, Dlouhy I, Salaverria I, Martin-Subero JI, Lopez-Guillermo A, Valera A, Campo E; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).

Am J Surg Pathol. 2017 Jul;41(7):877-886. doi: 10.1097/PAS.0000000000000839. Erratum in: Am J Surg Pathol. 2019 Mar;43(3):434.

PMID:
28288039
20.

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

Senín A, Broquetas T, Cañete N, Lens S, Londoño MC, Ferraro M, Forns X, Salar A, Carrión JA.

Ann Hepatol. 2017 March-April;16(2):312-317. doi: 10.5604/16652681.1231593.

21.

Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.

Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators.

Br J Haematol. 2017 Mar;176(6):918-928. doi: 10.1111/bjh.14489. Epub 2017 Jan 20.

PMID:
28106247
22.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A.

Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18.

PMID:
28101592
23.

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment.

Senín A, Broquetas T, Lens S, Cañete N, Londoño MC, Ferraro M, Forns X, Salar A, Carrión JA.

Ann Hepatol. 2017 Mar - Apr;16(2):312-317. doi: 10.5604/16652681.1231595.

24.

MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.

Fernández C, Bellosillo B, Ferraro M, Seoane A, Sánchez-González B, Pairet S, Pons A, Barranco L, Vela MC, Gimeno E, Colomo L, Besses C, Navarro A, Salar A.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):75-82.

25.

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).

Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO).

Haematologica. 2017 Feb;102(2):235-245. doi: 10.3324/haematol.2016.149120. Epub 2016 Oct 20.

26.

Blastic Plasmacytoid Dendritic Cell Neoplasm Associated with Dystrophic Xanthomatosis after Chemotherapy.

García-Colmenero L, Gallardo F, Salar A, Alvarez-Larrán A, Colomo L, Pujol RM.

Acta Derm Venereol. 2017 Feb 8;97(2):293-294. doi: 10.2340/00015555-2515. No abstract available.

27.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

28.

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18.

PMID:
27188649
29.

Turbulent Atmosphere-Based Dominant Management Behavior of the Head Nurses in Clinical Wards: A Qualitative Study.

Salar AR, Ahmadi F, Navipour H.

Iran Red Crescent Med J. 2016 Feb 28;18(2):e21754. doi: 10.5812/ircmj.21754. eCollection 2016 Feb.

30.

Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.

Sabater E, López-Guillermo A, Rueda A, Salar A, Oyagüez I, Collar JM.

Appl Health Econ Health Policy. 2016 Aug;14(4):465-477. doi: 10.1007/s40258-016-0243-4.

PMID:
27090915
31.

Rice bran oil and canola oil improve blood lipids compared to sunflower oil in women with type 2 diabetes: A randomized, single-blind, controlled trial.

Salar A, Faghih S, Pishdad GR.

J Clin Lipidol. 2016 Mar-Apr;10(2):299-305. doi: 10.1016/j.jacl.2015.11.016. Epub 2015 Dec 7.

PMID:
27055960
32.

Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.

González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group.

Ann Hematol. 2016 May;95(6):893-9. doi: 10.1007/s00277-016-2648-4. Epub 2016 Mar 30.

33.

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.

Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO).

Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5.

PMID:
26847165
34.

Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Freyer G, Kalinka-Warzocha E, Syrigos K, Marinca M, Tonini G, Ng SL, Wong ZW, Salar A, Steger G, Abdelsalam M, DeCosta L, Szabo Z.

Med Oncol. 2015 Oct;32(10):236. doi: 10.1007/s12032-015-0682-z. Epub 2015 Aug 28.

PMID:
26315712
35.

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV.

Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9.

PMID:
26179864
36.

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.

Fernández-Rodríguez C, Salar A, Navarro A, Gimeno E, Pairet S, Camacho L, Ferraro M, Serrano S, Besses C, Bellosillo B, Sanchez-Gonzalez B.

Leuk Lymphoma. 2016;57(3):692-9. doi: 10.3109/10428194.2015.1063143.

37.

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Gutiérrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez-Serra J, Sanchez B, Martorell C, Gines J, Garcia L, Gimeno E, Ferraro M, Del Campo R, Bargay J, Perez A, Vercher J, Scaff M, Pacheco A, Ballester C, Garcia F, Ramos R, Salar A, Besalduch J.

PLoS One. 2015 Apr 24;10(4):e0123978. doi: 10.1371/journal.pone.0123978. eCollection 2015.

38.

A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.

Rueda A, García-Sanz R, Pastor M, Salar A, Labrador J, Quero-Blanco C, Casanova M, Provencio M; Gotel and Geltamo.

Acta Oncol. 2015 Jun;54(6):933-8. doi: 10.3109/0284186X.2015.1007212. Epub 2015 Mar 3.

PMID:
25734915
39.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO).

Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19.

PMID:
27029228
40.

[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].

Ancochea Á, Salar A, García-Pallarols F, Gimeno E, Fernández-Rodriguez C, Sánchez-González B.

Med Clin (Barc). 2015 Jun 22;144(12):544-7. doi: 10.1016/j.medcli.2014.04.026. Epub 2014 Aug 8. Spanish.

PMID:
25110180
41.

Metronomic chemotherapy for advanced and refractory cutaneous T-cell lymphoma treatment.

López Aventín D, Gallardo F, Sanchez-Gonzalez B, Pujol RM, Salar A.

J Eur Acad Dermatol Venereol. 2016 Jan;30(1):136-8. doi: 10.1111/jdv.12624. Epub 2014 Jul 30. No abstract available.

PMID:
25073876
42.

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.

Fernández-Rodríguez C, Bellosillo B, García-García M, Sánchez-González B, Gimeno E, Vela MC, Serrano S, Besses C, Salar A.

Leukemia. 2014 Oct;28(10):2104-6. doi: 10.1038/leu.2014.184. Epub 2014 Jun 6. No abstract available.

PMID:
24903481
43.

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G.

J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12.

PMID:
24821885
44.

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.

Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.

Haematologica. 2014 Jul;99(7):1228-35. doi: 10.3324/haematol.2013.101741. Epub 2014 Apr 11.

45.

Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.

Sanchez-Gonzalez B, Gimeno E, Garcia-Pallarols F, Ancochea A, Salar A.

Leuk Lymphoma. 2014 Oct;55(10):2384-6. doi: 10.3109/10428194.2013.871280. Epub 2014 Mar 7. No abstract available.

PMID:
24601815
46.

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.

Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A; Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma.

Blood. 2014 Mar 20;123(12):1864-9. doi: 10.1182/blood-2013-11-537993. Epub 2014 Feb 5.

PMID:
24501214
47.

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.

Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, Puigdecanet E, Gimeno J, Garcia-Garcia M, Vela MC, Luño E, Collado R, Navarro JT, de la Banda E, Abrisqueta P, Arenillas L, Serrano C, Lloreta J, Miñana B, Cerutti A, Florensa L, Orfao A, Sanz F, Solé F, Dominguez-Sola D, Serrano S.

Clin Cancer Res. 2014 Feb 15;20(4):1007-19. doi: 10.1158/1078-0432.CCR-13-1077. Epub 2013 Dec 18.

48.

Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.

Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA.

Leukemia. 2014 Jun;28(6):1334-40. doi: 10.1038/leu.2013.365. Epub 2013 Dec 3.

PMID:
24296945
49.

Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.

Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A.

Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26.

PMID:
24274082
50.

Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.

González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695.

PMID:
23880897

Supplemental Content

Support Center